Japan Approves GSK's Bepirovirsen, First Functional Cure for Chronic Hepatitis B

GSK's bepirovirsen, branded Hibsago, has received its first global approval in Japan for chronic hepatitis B (CHB). This marks the first and only functional cure treatment for CHB approved in the country, aiming to eradicate the virus and its surface protein, a significant advance over existing virus-suppressing therapies.